We are live on ! Find out more
ORIC icon

Oric Pharmaceuticals
ORIC

112 hedge funds and large institutions have $879M invested in Oric Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 32 increasing their positions, 28 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,679% more call options, than puts

Call options by funds: $3.25M | Put options by funds: $117K

133% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 15

87% more capital invested

Capital invested by funds: $470M → $879M (+$409M)

22% more funds holding

Funds holding: 92 → 112 (+20)

14% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 28

1.21% more ownership

Funds ownership: 93.71% → 94.92% (+1.2%)

29% less funds holding in top 10

Funds holding in top 10: 7 → 5 (-2)

Holders
112
Holders Change
+20
Holders Change %
+21.74%
% of All Funds
1.61%
Holding in Top 10
5
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-28.57%
% of All Funds
0.07%
New
35
Increased
32
Reduced
28
Closed
15
Calls
$3.25M
Puts
$117K
Net Calls
+$3.13M
Net Calls Change
+$978K

Top Buyers

Rank Fund Capital Flow
1
Viking Global Investors
Viking Global Investors
Connecticut
+$47.5M
2
CC
Commodore Capital
New York
+$23.8M
3
FLSM
Frazier Life Sciences Management
California
+$23.8M
4
VA
VR Adviser
New York
+$23.4M
5
NMC
NEA Management Company
Maryland
+$17.8M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$23.5M
2
PM
Prosight Management
Texas
-$14.5M
3
Morgan Stanley
Morgan Stanley
New York
-$7.84M
4
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$6.07M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
-$4.79M
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
26
Soleus Capital Management
Connecticut
$5.79M +$5M +421,000 New
ACM
27
Altium Capital Management
New York
$5.57M -$3.22M -271,000 -40%
Northern Trust
28
Northern Trust
Illinois
$4.86M +$1.71K +144 +0%
Morgan Stanley
29
Morgan Stanley
New York
$4.14M -$7.84M -659,839 -69%
O
30
OrbiMed
New York
$3.95M -$2.8M -235,868 -45%
FAM
31
Fred Alger Management
New York
$3.02M +$2.61M +219,943 New
TD Asset Management
32
TD Asset Management
Ontario, Canada
$2.87M +$1.52M +127,800 +158%
Bank of America
33
Bank of America
North Carolina
$2.77M +$1.13M +95,432 +90%
Millennium Management
34
Millennium Management
New York
$2.71M +$2.34M +196,852 New
NIP
35
Nicholas Investment Partners
California
$2.52M +$2.18M +183,494 New
Goldman Sachs
36
Goldman Sachs
New York
$2.33M +$1.41M +118,890 +234%
Dimensional Fund Advisors
37
Dimensional Fund Advisors
Texas
$2.21M +$1.62M +136,126 +552%
Walleye Capital
38
Walleye Capital
New York
$2.05M +$1.77M +149,337 New
DCM
39
Driehaus Capital Management
Illinois
$1.98M – – –
N
40
Nuveen
North Carolina
$1.87M – – –
Citigroup
41
Citigroup
New York
$1.84M +$1.51M +127,343 +1,940%
MAM
42
Monaco Asset Management
Monaco
$1.79M -$1.78M -150,000 -54%
Manulife (Manufacturers Life Insurance)
43
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1.68M +$880K +74,095 +155%
Bank of New York Mellon
44
Bank of New York Mellon
New York
$1.58M -$42.6K -3,589 -3%
Wellington Management Group
45
Wellington Management Group
Massachusetts
$1.54M +$470K +39,576 +55%
Rafferty Asset Management
46
Rafferty Asset Management
New York
$1.53M +$1.32M +111,146 New
Renaissance Technologies
47
Renaissance Technologies
New York
$1.52M -$922K -77,600 -41%
Two Sigma Investments
48
Two Sigma Investments
New York
$1.5M +$47.5K +3,999 +4%
BC
49
BIT Capital
Germany
$1.49M +$1.29M +108,624 New
Charles Schwab
50
Charles Schwab
California
$1.44M -$24.4K -2,057 -2%
1
2
3 4 5

ORIC Hedge Fund Activity: Q1 2024 in Review

112 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Oric Pharmaceuticals (ORIC) for Q1 2024, worth a combined $879M — up 87% from $470M a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new ORIC positions and 15 closed out — a net gain of 20 holders — while 32 added to existing stakes and 28 trimmed.

The largest buyer was Viking Global Investors, opening a new position worth an estimated $47.5M. The largest seller was Fidelity Investments, cutting an estimated $23.5M.

  • 112 institutional investors held Oric Pharmaceuticals (ORIC) as of Q1 2024, up from 92 in Q4 2023.
  • Funds reported $879M of Oric Pharmaceuticals stock for Q1 2024, up 87% quarter-over-quarter.
  • 35 funds opened new Oric Pharmaceuticals positions in Q1 2024 and 15 closed out, a net change of +20 holders.
  • The largest Oric Pharmaceuticals buyer in Q1 2024 was Viking Global Investors, an estimated $47.5M added.
  • The largest Oric Pharmaceuticals seller in Q1 2024 was Fidelity Investments, an estimated $23.5M sold.

Based on aggregated 13F filings for Q1 2024.